Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
297 GBX | +0.68% | -8.05% | -15.74% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.74% | 385M | |
+7.83% | 219B | |
+6.06% | 183B | |
+11.14% | 132B | |
+23.88% | 106B | |
-2.66% | 62.09B | |
+4.81% | 50.88B | |
+11.00% | 50.8B | |
-0.78% | 40.64B | |
+25.27% | 31.59B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- Craig-Hallum Starts Coverage on MaxCyte with Buy Rating, $7 Price Target